CTOs on the Move

Aurinia Pharmaceuticals

www.auriniapharma.com

 
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat identifiable patient populations that are suffering from serious diseases with a high unmet medical need. The company is headquartered in Victoria, BC and focuses its development efforts globally.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.auriniapharma.com
  • 500 W Office Center Drive Suite 400
    Fort Washington, PA USA 19034
  • Phone: 250.708.4272

Executives

Name Title Contact Details
Darin Wilson
Senior Director, Enterprise IT Profile

Funding

Aurinia Pharmaceuticals raised $28.75M on 12/29/2016
Aurinia Pharmaceuticals raised $173.1M on 03/20/2017
Aurinia Pharmaceuticals raised $191.7M on 12/12/2019

Similar Companies

Cryofab

Cryofab is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arbor Vita Corporation

Arbor Vita Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verano Holdings

Verano™ Holdings is a national, vertically-integrated operator of licensed cannabis cultivation, manufacturing and retail facilities dedicated to improving lives by providing safe access to effective organic cannabis products that enhance health and wellness and by positively impacting the communities it serves.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Nura Inc

Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.